Navigation Links
Genetic analysis reveals range of Rett syndrome
Date:3/11/2008

The first comprehensive analysis of the clinical effects of genetic mutations involved in Rett syndrome will enable affected families to receive a more accurate indication of their childs prognosis.

The research was undertaken by an international collaboration based on information provided by families and clinicians from around the world to the InterRett online database at the Telethon Institute for Child Health Research.

The results have just been published in the March edition of the prestigious international journal Neurology.

Report co-author, Dr Helen Leonard, who heads the Australian Rett Syndrome Study, said the findings have revealed a wide variability in the effects of the syndrome.

This is the first time that weve had quality information about a sufficient number of cases to be able to do a rigorous analysis comparing specific genetic mutations with they way the disorder is manifested in affected girls, Dr Leonard said.

While Rett syndrome is caused by a mutation on the MECP2 gene on the X chromosome, variations in the mutation determine the severity of symptoms.

Our analysis of eight common mutations that account for two-thirds of cases, showed considerable variation in abilities

Dr Leonard said the information would be of great value to families, clinicians and carers.

Many parents have found the lack of information about their daughters prognosis very distressing and will welcome a clearer indication of what they might expect in the future, Dr Leonard said.

Our findings really emphasised how much variability there is in the syndrome and we hope that information will assist with earlier diagnosis.

Dr Leonard said that girls with the milder form of Rett syndrome may retain some language, hand function and the ability to walk. In contrast, those with the severe form dont show the usual pattern of regression but are affected from birth.


'/>"/>

Contact: Liz Chester
elizabeth@ichr.uwa.edu.au
61-894-897-965
Research Australia
Source:Eurekalert

Page: 1

Related medicine news :

1. Genetic research unveils common origins for distinct clinical diagnoses
2. New stem cell technique improves genetic alteration
3. Einstein researchers genetically engineer immune cells into potent weapons for battling HIV
4. Genetic Test Predicts Response to Warfarin
5. New revelations in epigenetic control shed light on breast cancer
6. Researchers identify new genetic marker for breast cancer
7. Anti-Aging/Genetic Health Leader Suracell, Inc. Expands Internationally
8. Adult stem cell changes underlie rare genetic disease associated with accelerated aging
9. Genetic Factors for Smoking Boost Chronic Bronchitis Risk
10. Genetic factors in smoking also increase risk of chronic bronchitis
11. Dr. Robert Leonard First in New England to Offer Genetic Test for Male Pattern Baldness
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Reportlinker Adds Radiation Therapy Equipment - A Global Market Review 2Reportlinker Adds Radiation Therapy Equipment - A Global Market Review 3Reportlinker Adds Radiation Therapy Equipment - A Global Market Review 4Reportlinker Adds Radiation Therapy Equipment - A Global Market Review 5Reportlinker Adds Radiation Therapy Equipment - A Global Market Review 6Reportlinker Adds Radiation Therapy Equipment - A Global Market Review 7Reportlinker Adds Radiation Therapy Equipment - A Global Market Review 8Particle Sciences and IES Engineers Cooperate on High Potency Compound Handling Capabilities 2Particle Sciences and IES Engineers Cooperate on High Potency Compound Handling Capabilities 3Global Announces Contract To Acquire New Business 2Wound Management Technologies Inc Announced Today That It Has Reached an Agreement in Principal to Acquire BioPharma Management Technologies Inc 12648 1Wound Management Technologies Inc Announced Today That It Has Reached an Agreement in Principal to Acquire BioPharma Management Technologies Inc 12648 2Carbon Design Innovations Inc Introduces Carbon Nanotube Probe Technology for Atomic Force Microscopy CNT Probes Deliver New Level of AFM Imaging P 12645 1Carbon Design Innovations Inc Introduces Carbon Nanotube Probe Technology for Atomic Force Microscopy CNT Probes Deliver New Level of AFM Imaging P 12645 2Carbon Design Innovations Inc Introduces Carbon Nanotube Probe Technology for Atomic Force Microscopy CNT Probes Deliver New Level of AFM Imaging P 12645 3Finances Trigger American Reluctance to Spend More on Healthier Foods 49018 1Finances Trigger American Reluctance to Spend More on Healthier Foods 49018 2
Other Medicine Technology:Biomira Selects PX-866 as Clinical Development Candidate and,Presents Promising Preclinical Data at AACR 2Biomira Selects PX-866 as Clinical Development Candidate and,Presents Promising Preclinical Data at AACR 3Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 2Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 3Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 4Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 5Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 6Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 7Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 8Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 9